Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany.
Am J Transplant. 2011 Nov;11(11):2443-52. doi: 10.1111/j.1600-6143.2011.03693.x. Epub 2011 Aug 10.
Impaired BKV-specific immunity is associated with development of BKV-associated nephropathy. Suitable immunological parameters to identify patients at risk, however, are still debated. We monitored 18 kidney-transplant recipients through the course of self-limited BKV-reactivation (n = 11) and BKV-associated nephropathy (n = 7). BKV-specific cellular immunity directed to nonstructural small and Large T-antigen, and structural VP1-3 was analyzed in an interferon-γ Elispot assay. BKV-specific IgM and IgG were measured using an enzyme-linked immunosorbent assay simultaneously. BKV-specific cellular immunity directed to five BKV-proteins increased significantly from diagnosis to resolution of BKV-reactivation (p < 0.001). Patients with self-limited BKV-reactivation developed BKV-specific T cells without therapeutic interventions, and cleared BKV-reactivation within a median period of 1 month. Patients with BKV-associated nephropathy, however, showed BKV-specific T cells after a median period of 5 months after therapeutic interventions only, and cleared BKV-reactivation after a median period of 8 months. Anti-structural T cells were detected earlier than anti-nonstructural T cells, which coincided with BKV-clearance. Patients with BKV-associated nephropathy showed the highest frequencies of BKV-specific T cells at recovery, the highest increase in BKV-specific IgG and persistence of increased IgM levels (p < 0.05). Our results suggest prognostic values of BKV-specific immune monitoring to identify those patients at risk of BKV-associated nephropathy and to aid in the management of therapeutic interventions.
BKV 特异性免疫受损与 BKV 相关性肾病的发生有关。然而,用于识别高危患者的合适免疫参数仍存在争议。我们通过对 18 例肾移植受者进行监测,这些受者经历了自限性 BKV 再激活(n=11)和 BKV 相关性肾病(n=7)。通过干扰素-γ Elispot 分析检测针对非结构小和大 T 抗原以及结构 VP1-3 的 BKV 特异性细胞免疫。同时使用酶联免疫吸附试验测量 BKV 特异性 IgM 和 IgG。从 BKV 再激活的诊断到缓解,针对五种 BKV 蛋白的 BKV 特异性细胞免疫显著增加(p<0.001)。具有自限性 BKV 再激活的患者在没有治疗干预的情况下产生了 BKV 特异性 T 细胞,并在中位数为 1 个月的时间内清除了 BKV 再激活。然而,患有 BKV 相关性肾病的患者仅在治疗干预后中位数 5 个月后才出现 BKV 特异性 T 细胞,并在中位数 8 个月后清除 BKV 再激活。抗结构 T 细胞比抗非结构 T 细胞更早被检测到,这与 BKV 清除相一致。在恢复时,患有 BKV 相关性肾病的患者表现出最高频率的 BKV 特异性 T 细胞、BKV 特异性 IgG 最高增加以及持续升高的 IgM 水平(p<0.05)。我们的结果表明,BKV 特异性免疫监测具有预后价值,可以识别那些有发生 BKV 相关性肾病风险的患者,并有助于治疗干预的管理。